Madhav Kamat
Madhav Kamat Ph.D R.Ph.

President & Chief Executive Officer

Dr. Kamat has 30+ years of industrial experience in large pharmaceutical companies specializing in the area of sterile injectable products and processes. He worked for eight years at Centocor, Johnson & Johnson, and Somatogen. Dr. Kamat worked at Bristol-Myers Squibb Company for seventeen years – most recently as a Director in Manufacturing Technology of Sterile/Biologics products.

He is a recognized expert in the fields of lyophilization, nano-suspension technology, aseptic technology, and other sterile manufacturing processes. Following is a list of some products that Dr. Kamat was involved in development/launch/support:

o Biologicals: Yervoy, Nulojix IV, Orencia SC and IV, Erbitux, Remicade, Repro
o Small molecules: Ixempra, Tequin, Ketorolac, and Acyclovir
o Cytotoxics: Taxol, BicNu, Cytoxan, Carboplatin, Doxorubicin, Mutamycin, Etopophos
o Unique: Kenalog: Steroidal IM suspension product

In the last few years, Dr. Kamat has led Kamat Pharmatech provide extensive CMC development support to >10 innovative biotech companies as well as large pharmaceutical companies.


Dr. Kamat serves as a registered pharmacist in the States of New Jersey and Pennsylvania.
Dr. Kamat also serves as a course director for "Lyophilization Technology" by CfPA in the US, Europe, and ROW.